Physician profile
Jennifer Veverka
NPI 1205891694
$283,235.53
in general payments reported to CMS, 2019-2025
21 companies · $73K in 2025
The $73K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,357 · 2020: $1,255 · 2021: $31K · 2022: $44K · 2023: $66K · 2024: $60K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Travel and Lodging: $16K · Food and Beverage: $8,003 · Consulting Fee: $1,900 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173,463.11 |
| Travel and Lodging | $15,510.23 |
| Food and Beverage | $8,002.56 |
| Consulting Fee | $1,900.00 |
| Education | $110.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153,420.74 | 2019-2025 | |
| Janssen Biotech, INC. | $64,248.60 | 2022-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $50,456.95 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $10,143.82 | 2021-2025 | Entyvio, Eohilia |
| Celgene Corporation | $3,686.12 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $211.98 | 2020-2025 | Pipeline, Tremfya |
| Boston Scientific Corporation | $203.58 | 2023-2025 | Exalt Model D, Resolution 360 Clip |
| Pfizer INC. | $146.04 | 2024-2025 | |
| Johnson & Johnson Health Care Systems INC. | $130.62 | 2024-2025 | Tremfya |
| Celltrion USA INC. | $118.46 | 2024-2025 | Vegzelma, Zymfentra |
| Madrigal Pharmaceuticals | $104.90 | 2025 | Rezdiffra |
| Lilly USA, LLC | $84.80 | 2023 | |
| Phathom Pharmaceuticals, INC. | $78.01 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $50.07 | 2023-2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $31.45 | 2024 | Bylvay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $28.96 | 2022 | |
| Qol Medical, LLC | $26.04 | 2022 | |
| Aimmune Therapeutics, INC. | $19.69 | 2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $18.11 | 2022 | |
| Braintree Laboratories, INC. | $14.65 | 2025 | Suflave |
| Allergan, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Veverka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.